SIRPG

Across TCGA pan-cancer cohorts, SIRPG Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SIRPG data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher SIRPG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SIRPG expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, SKCM, and KIRP are the cancer types where SIRPG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	III,IV	0.230	0.579	.015	18	view →
SKCM	OS	Median	All	0.211	0.348	.004	13	view →
KIRP	OS	Median	All	0.101	0.688	.002	12	view →
COAD	OS	Median	All	0.556	0.870	.024	6	view →
UCEC	DFS	Median	All	0.946	0.628	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SIRPG–ESCA (OS)

Open the ESCA breakdown →